Here's a recap of blog posts and other news from the past month.
The key point here is the difficulty in talking about the effects of treatment. If a drug has been linked by its manufacturer to an outcome like homicide, and if a case can be made that the drug had this effect in a particular individual, then we have a major problem if this defence cannot be used. A jury can decide whether it agrees or not, but if they are not given the chance to hear this argument, then this is bad news for all of us.
Blog posts over the next month will return to this from another perspective.
Thank you for your support.
Your feedback, as always, is greatly appreciated.
David Healy, MD
|